Molecular Dx firm Biocartis raises $45M in Series D financing

12/16/2012 | Clinica (subscription required)

Biocartis has secured $45 million in a Series D funding round, which it aims to use to increase its menu of cancer assays that run on the Apollo molecular diagnostics system. The Apollo platform, which the Swiss company purchased from Philips two years ago, is set to be introduced in Europe next year.

View Full Article in:

Clinica (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR